Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.48 |
| ▸ | PRKACA | P17612 | 3/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897260 | 0.89 | ESRRG (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13068824 | 0.77 | HPGD (0.60) | MAOBROCK1PRKACAGSK3AGSK3B | |
| SCHEMBL4897032 | 0.76 | HPGD (0.55) | MAOBTP53ROCK1PRKACAGSK3A | |
| SCHEMBL12788248 | 0.75 | PPARA (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4895408 | 0.72 | CSNK2A2 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12272660 | 0.72 | MAOB (0.46) | MAOBTP53ROCK1GSK3AGSK3B | |
| SCHEMBL12272209 | 0.71 | MAOB (0.45) | MAOBROCK1GSK3AGSK3BCLK4 | |
| SCHEMBL26625669 | 0.70 | MMP13 (0.64) | HDAC1HDAC2HDAC8HDAC6HDAC5 | |
| SCHEMBL28443491 | 0.70 | HSD17B1 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL24565478 | 0.70 | HDAC1 (0.74) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | SGK1, SGK2, SGK3 | HDAC3 456/4885HDAC4 710/4885HDAC1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.